Under a tenth of patients who could benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it releases its initial advice on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, over two billion will be obese by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be treated with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key barriers to universal availability to the treatments that can aid individuals in losing significant body mass, notes the organization.
GLP-1 Therapy Shortage
Even under the present most favorable scenario, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of eligible patients, according to the health organization.
The guideline urges nations and manufacturers to widen availability, through strategies such as voluntary licensing.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Obesity Drugs Work
These medications replicate a biological compound to slow digestion, curb appetite and enhance satiety so users eat less.
Individuals typically see weight reduction within a few weeks of commencing the once-weekly jabs.
Evidence indicates patients may put most of the weight back on a year later of discontinuing the drug, as their typical hunger come back.
Being overweight or obese elevates your risk for developing diseases, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity impacts people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.
